|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Infant acute lymphoblastic leukemia with lysine (K)-specific methyltransferase 2A (KMT2A) rearrangements usually has a poor prognosis regardless of the fusion partners of KMT2A.
|
30869817 |
2019 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy.
|
27841777 |
2017 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we provide additional evidence that they should be tested for their efficacy in MLL-rearranged infant ALL in in vivo models.
|
21116279 |
2011 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the influence of MLL/AF4 and AML1/MTG8 fusion genes on the expression of TERT coding for the telomerase protein subunit, and subsequently telomerase activity in t(4;11)-positive ALL and t(8;21)-positive cell lines, respectively.
|
20686504 |
2010 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
|
15956279 |
2005 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CDK6 mRNA was significantly higher expressed in MLL-rearranged infant ALL patients compared with MLL wild-type ALL patients (P < 0.001).
|
24736461 |
2014 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 11q23/MLL involvement of blast cells identifies a major subgroup of infant ALL cases that require an innovative treatment approach.
|
8164041 |
1994 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Simultaneous involvement of 11q23 translocation resulting in chimeric MLL-AFF1 and a second translocation [t (9;21) (p13; p11.2)] in an infant acute lymphoblastic leukemia patient at relapse: A case report.
|
29794792 |
2018 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genes that were affected in response to the repression of AF4-MLL showed significant enrichment in gene expression profiles associated with AF4-MLL expressing t(4;11)+ infant ALL patient samples.
|
25793396 |
2015 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report two cases of chemotherapy-sensitive non-KMT2A-r infant ALL.
|
31515871 |
2020 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that an elevated expression of hENT1, which transports Ara-C across the cell membrane, contributes to Ara-C sensitivity in MLL gene-rearranged infant ALL.
|
12406912 |
2003 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We, therefore, specifically addressed the question whether the reactivity of moab 7.1, as determined by flow cytometry, may substitute for molecular testing of an 11q23/MLL rearrangement in this cohort of infant ALLs.
|
12200682 |
2002 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The category of infant ALL patients carrying a translocation involving the mixed lineage leukemia (MLL) gene (gene KMT2A) is characterized by resistance to GCs and poor clinical outcome.
|
31370801 |
2019 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also extended and updated our original study of MLL gene rearrangement in infant ALL to 40 patients with longer follow-up and show that the group with germline configuration of the MLL gene continues to have an excellent outcome.
|
7579356 |
1995 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The majority of MLL gene rearrangements are associated with infant ALL, and their presence predicts a poor prognosis which worsens with earlier age of presentation.
|
17905612 |
2008 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The siblings were diagnosed with MLL-rearranged (MLL-R) ALL 26 months apart.
|
26999444 |
2016 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rearrangements of the mixed-lineage leukemia (MLL) gene have been associated with a poor prognosis in infant acute lymphoblastic leukemia (ALL).
|
16843104 |
2006 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, allogeneic HSCT using BU was a valuable option for infant ALL with KMT2A rearrangements in CR1.
|
25302748 |
2015 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In common with other neonatal or infant ALL with MLL gene rearrangements, this leukaemia may have originated in a common B-monocytic lineage stem cell during foetal haemopoiesis.
|
8609712 |
1995 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Levels of minimal residual disease (MRD) at the end of induction appeared to be high in infants with ALL compared with older children, and although the number of infant cases studied was small, there were no differences in MRD levels after induction therapy in infant ALL with or without MLL gene rearrangements (P = 0.41) and quantitative MRD assessment at the early time points may not be predictive of outcome.
|
16197448 |
2005 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
|
23958920 |
2014 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data endorse the notion that infant ALL with MLL fusion genes have a unique etiology possibly involving transplacental exposure to chemicals.
|
16266898 |
2005 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this context, this mini-review summarizes the available data surrounding MLL-r infant ALL with RAS mutation in relation to other well-known features of this intriguing disease.
|
29056538 |
2017 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
|
16357833 |
2006 |
|
Infant Acute Lymphoblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with de novo leukemias with MLL translocations were significantly more likely to be heterozygous at NQO1 C609T (odds ratio [OR] = 2.77, 95% confidence intervals [CI] 1.17-6.57; P =.02), and significantly more likely to have low/null NQO1 activity than patients with de novo B-lineage ALL without MLL translocations (OR = 2.47, 95% CI 1.08-5.68; P =.033).
|
12393620 |
2002 |